AtmosR Alternatives & Competitors
12 companies similar to AtmosR — Pioneering treatments to restore autonomous breathing and safety for those with...
Companies similar to AtmosR
Travecta Therapeutics
Pioneering advancements in central nervous system treatments with innovative solutions for...
Cerebral Therapeutics, Inc.
A clinical stage pharmaceutical company developing innovative treatments for neurological...
Umecrine Cognition AB
A novel and safe approach for treating cognitive disorders
Emalex Biosciences
Improving people's lives impacted by central nervous system disorders through meaningful s...
Rival Readout
Competing with AtmosR? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
CNS Therapeutics
Delivering advanced neurological and pain treatments with precision and expertise
Disarm Therapeutics
Creating advanced therapeutics to combat axonal degeneration and treat neurological diseas...
Praxis Precision Medicines, Inc.
The era of genetic neuroscience has arrived
Apic Bio
Pioneering gene therapies for rare neurological and liver diseases, targeting Alpha-1 Anti...
Hoba Therapeutics
Developing Restorative Treatments for Chronic Neuropathic Pain and Hearing Loss
Acadia Pharmaceuticals
Acadia is trailblazing breakthroughs in neuroscience to elevate life.
XWPharma
Neuroscience biotech developing novel therapeutics for sleep, neuropsych, and other unders...
Chance Pharmaceuticals 畅溪制药
A clinical-stage biotech company focusing on discovering, developing and commercializing i...
About AtmosR
AtmosR is a biotech startup that focuses on developing pioneering treatments for rare and severe disorders of the central nervous system. Their flagship drug, ATS-003, aims to restore autonomous breathing in CCHS patients, thus eliminating a critical risk and enabling greater independence. Founded in 2019, the company...
Biotech Company, Central Nervous System Disorders, ATS-003, Rare Disorders, Autonomous Breathing, CCHS Patients, Innovative Treatments, Aix En Provence, Paris, Drug Development, Rare Disease, Neurological Disorders
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around AtmosR: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at AtmosR on 26 Jul 2024. The 12 companies listed here were last checked between 11 Sep 2024 and 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.